Bart Barolgie, MD, Joins Tisch Cancer Institute at Mount Sinai


Get Permission

Bart Barlogie, MD

Bart Barlogie, MD, a myeloma expert who introduced the first curative therapy for multiple myeloma, a multidrug regimen known as Total Therapy 3, is joining the faculty of Tisch Cancer Institute of the Icahn School of Medicine at Mount Sinai (ISMM. Dr. Barlogie will serve as Director of Research in the Myeloma Program led by Sundar Jagannath, MD, Professor of Hematology and Medical Oncology at ISMM.

 “I am excited to collaborate with Sundar and other elite scientists to find novel approaches for patients with high-risk myeloma. We have a unique opportunity to move the field forward, and our understanding of the underlying mechanisms in the transition to malignant disease,” said Dr. Barlogie.

Dr. Barlogie’s work has focused on biologic and therapeutic research, including chemotherapy, immunotherapy, and hematopoietic stem cell transplantation. Among his seminal contributions are the developments of the VAD regimen for refractory myeloma, autologous stem cell supported high dose therapy, tandem transplants, and thalidomide.

Many new biologic insights have been gained through Dr. Barlogie’s research, notably, the identification of chromosome 13 deletions as a separate high-risk entity in myeloma, and more recently, the identification of distinct risk-stratified subgroups of myeloma. 

Earlier Work

Prior to joining Mount Sinai, Dr. Barlogie served for 20 years as Director of Myeloma Institute for Research & Therapy at University of Arkansas for Medical Sciences (UAMS), an Institute he founded. Under his leadership, the Institute became a world-renowned program and was recently awarded a $10 million grant to create the Bart Barlogie Center for Molecular Diagnostics and the Celgene Distinguished Endowed Chair in Molecular Therapeutics at UAMS. 

Dr. Barlogie is a Fellow of the American College of Physicians, and has served on the Board of Directors of the International Myeloma Foundation. He currently serves on the editorial boards of Annals of Hematology, Blood, Clinical and Experimental Medicine, Clinical Cancer Research, Clinical Lymphoma & Myeloma, Current Cancer Therapy Reviews, Clinical Myeloma, International Journal of Clinical Oncology, Oncologie, and The Oncologist

Dr. Barlogie earned his postgraduate degrees at Heidelberg University and the Max Planck Institute for Medical Research in Germany. Following residency at the Universities of Munich and Muenster, he joined MD Anderson Hospital and Tumor Research Institute as a fellow. ■


Advertisement

Advertisement



Advertisement